Trial Outcomes & Findings for Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT) (NCT NCT01004718)

NCT ID: NCT01004718

Last Updated: 2021-05-18

Results Overview

Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

2 hours (between 60 minutes post-administration and 180 minutes post-administration)

Results posted on

2021-05-18

Participant Flow

Participant milestones

Participant milestones
Measure
Fludeoxyglucose F18 (FDG) PET/CT Scans
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration. Fludeoxyglucose F18: Undergo FDG PET/CT scans Computed Tomography: Undergo FDG PET/CT scans Positron emission tomography: Undergo FDG PET/CT scans
Overall Study
STARTED
10
Overall Study
COMPLETED
10
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Fludeoxyglucose F18 (FDG) PET/CT Scans
n=10 Participants
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration. Fludeoxyglucose F18: Undergo FDG PET/CT scans Computed Tomography: Undergo FDG PET/CT scans Positron emission tomography: Undergo FDG PET/CT scans
Age, Continuous
47 years
n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
6 Participants
n=5 Participants
Region of Enrollment
United States
10 participants
n=5 Participants

PRIMARY outcome

Timeframe: 2 hours (between 60 minutes post-administration and 180 minutes post-administration)

Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).

Outcome measures

Outcome measures
Measure
Diffuse Large B-cell Lymphoma
n=5 Participants
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
Hodgkin's Lymphoma
n=5 Participants
Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration
36.2 percentage of change in maximum SUV
Standard Deviation 12.4
32 percentage of change in maximum SUV
Standard Deviation 11.6

Adverse Events

Fludeoxyglucose F18 (FDG) PET/CT Scans

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Ellen Napier, CRNP

University of Pennsylvania

Phone: 215.279.1972

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place